Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks, emphasizing broad wellness principles and preventive care. Within this framework, discussions of medication safety have traditionally focused on common side effects and general population guidelines. However, as clinical knowledge advances, the need arises to transition from these broad health contexts toward more specific occupational exposure concerns. In mass production environments, workers may encounter pharmaceutical compounds or their precursors during manufacturing processes, creating potential pathways for unintended exposure. This shift in perspective requires careful consideration of how substances like bisphosphonates, originally developed for general health indications, might pose distinct risks in occupational settings. The focus moves from patient-centered medication management to worker safety protocols, where chronic low-level exposure or acute contact during production could lead to health outcomes not typically addressed in general health literature. This transition acknowledges that the same chemical agents discussed in public health contexts may present unique challenges when encountered in industrial environments, necessitating specialized risk assessment and monitoring strategies that bridge general health knowledge with occupational medicine principles.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the need for specialized risk assessment, this article examines Fosamax (alendronate), a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition involving bone death in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region, often following dental procedures such as tooth extraction, dental implants, or boney surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis is based on clinical examination and history, with imaging studies sometimes used to assess the extent of bone involvement.

Mechanisms Linking Fosamax to Osteonecrosis of the Jaw

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which is the intended therapeutic effect for osteoporosis treatment. However, this suppression of bone turnover may impair the jawbone's ability to repair microdamage and maintain normal remodeling. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided information that can help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the structural and mechanical properties of jawbone, potentially contributing to ONJ development.

Risk Factors and Temporal Considerations

Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies such as chemotherapy, corticosteroids, and angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with the duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms after starting the drug has been reported to range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Evidence Summary

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ development, as well as ruling out other potential causes such as cancer, concomitant therapies, or dental procedures. The known risk factors for ONJ, including invasive dental procedures and co-morbid disorders, must be evaluated in each case (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The evidence from animal studies supports a biological plausibility for bisphosphonate-induced changes in jawbone that could contribute to ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). The recurrence of symptoms upon rechallenge with bisphosphonates further supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw under warnings and precautions. This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax exposure has been linked to osteonecrosis of the jaw through clinical reports and mechanistic studies. The condition is associated with known risk factors and can occur after variable durations of exposure. Warnings in the prescribing information address this risk, and discontinuation of treatment may reduce risk in certain clinical scenarios.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition involving bone death in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fosamax (alendronate) is a bisphosphonate that has been reported to cause ONJ in some patients. The mechanism involves suppression of bone turnover, impairing the jawbone's ability to repair microdamage (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms after starting Fosamax has been reported to range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, and most patients had relief after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What should I do if I have been taking Fosamax and need dental surgery?

For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). It is important to discuss your medication history with your dentist and healthcare provider to assess the risks and benefits of stopping Fosamax temporarily.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.